Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY2409021 in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY2409021Drug: Placebo
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 263
- Registration Number
- NCT01241448
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville, Spain
A Study of LY2216684 in Participants With Impaired Hepatic Function
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT01241435
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Study of LY2584702 in Solid Tumors
- Conditions
- Cancer
- Interventions
- Drug: LY2584702
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT01241461
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan
Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01237899
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zuidlaren, Netherlands
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 184
- Registration Number
- NCT01237587
- Locations
- 🇵🇷
Centro de Investigaciones Clinicas, San Juan, Puerto Rico
🇺🇸Synergy Clinical Research, National City, California, United States
🇺🇸Northwest Clinical Research Center, Bellevue, Washington, United States
A Study of LY2439821 in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: LY2439821
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01236118
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject
- Conditions
- Insomnia
- Interventions
- Drug: LY2624803Other: Activated Charcoal
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01236105
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT01234402
- Locations
- 🇨🇦
ImClone Investigational Site, Toronto, Ontario, Canada
A Study in Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 172
- Registration Number
- NCT01232452
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zeytinburnu, Turkey
A Study of Brain Receptor Occupancy in Healthy Subjects
- Conditions
- Alcohol Dependence
- Interventions
- Drug: opioid receptor kappa antagonist
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT01232439
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States